Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nirmatrelvir/Ritonavir in Hepatic Impairment
NCT05005312Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at Day 3, Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration at Day 3 and 1 more. Started Aug 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05005312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005312.